

1634

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/500,135

F: 09/01/2000

TIME: 12:13:00

Input: Get: Ar\A688931.app

Output: Set: N:\CRF3\08012000\I500135.raw

Does Not Comp  
Corrected Diskette New

1 111- APPLICANT: Estell, David  
 1 112- Filing: Filing  
 1 113- TITLE OF INVENTION: PEPTIDES PROTECTING AN ALBIUM MONOMER FROM AGGREGATION AND  
 1 114- METHODS OF MAKING AND USING THE SAME  
 1 115- FILE REFERENCE: A-88 3/DJB/DAY  
 1 116- CURRENT APPLICATION NUMBER: 09/500,135  
 1 117- CURRENT FILING DATE: 1999-03-08  
 1 118- PRIOR APPLICATION NUMBER: 09/060,872  
 1 119- PRIOR FILING DATE: 1998-01-15  
 1 120- NUMBER OF SEQ. ID NOS.: 3  
 1 121- SOFTWARE: PatentIn Ver. 2.1  
 1 210- SEQ ID NO: 1  
 1 211- LENGTH: 119  
 1 212- TYPE: DNA  
 1 213- ORGANISM: *Escherichia coli* O157:H7  
 1 214- FEATURE:  
 1 215- NAME/KEY: mat peptide  
 1 216- LOCATION: (1)..(119)  
 1 217- FEATURE:  
 1 218- NAME/KEY: CTS  
 1 219- LOCATION: (79)..(114)  
 1 220- FEATURE:  
 1 221- NAME/KEY: unsure  
 1 222- LOCATION: (66)..(78)  
 1 223- OTHER INFORMATION: The aa at positions 66 through 78 represents aa  
 1 224- which is to code for methionine.  
 1 225- FEATURE:  
 1 226- NAME/KEY: unsure  
 1 227- LOCATION: (58)..(78)  
 1 228- OTHER INFORMATION: The aa at positions 58 through 78 represents  
 1 229- aa, which in a preferred embodiment (aa) is to  
 1 230- code for asparagine, but which may also code for  
 1 231- proline.  
 1 232- FEATURE:  
 1 233- NAME/KEY: unsure  
 1 234- LOCATION: (58)..(78)  
 1 235- OTHER INFORMATION: The aa at positions 58 through 78 represents  
 1 236- aa, which in a preferred embodiment (aa) is to  
 1 237- code for proline, but which may also code for  
 1 238- asparagine.  
 1 239- FEATURE:  
 1 240- NAME/KEY: unsure  
 1 241- LOCATION: (49)..(59)  
 1 242- OTHER INFORMATION: The aa at positions 49 to 59 represents aa  
 1 243- which in a preferred embodiment (aa) is to code  
 1 244- for asparagine, but which may also code for  
 1 245- aspartic acid.

pg 4-5

FYI:  
 C? gtg code for  
 valine

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/500,135

DATE: 03/01/2000

TIME: 12:07:00

Input Set: A:\A688931.app

Output Set: N:\CRE3\08012000\I500135.raw

```

61 120- FEATURE:
62 121- NAME/KEY: unsure
63 122- LOCATION: (120)...(120)
64 123- OTHER INFORMATION: The num at positions 120 through 120 represents
65     Aaa, which in a preferred embodiment (aa) is to
66     code for alanine, but which may also code for
67     serine.
68 124- FEATURE:
69 125- NAME/KEY: unsure
70 126- LOCATION: (121)...(121)
71 127- OTHER INFORMATION: The num at positions 121 through 121 represents
72     Aaa, which in a preferred embodiment (aa) is to
73     code for serine, but which may also code for
74     alanine.
75 128- FEATURE:
76 129- NAME/KEY: unsure
77 130- LOCATION: (122)...(122)
78 131- OTHER INFORMATION: The num at positions 122 through 122 represents
79     Aaa, which in a preferred embodiment (aa) is to
80     code for alanine, but which may also code for
81     aspartic acid.
82 132- FEATURE:
83 133- NAME/KEY: unsure
84 134- LOCATION: (123)...(123)
85 135- OTHER INFORMATION: The num at positions 123 through 123 represents
86     Aaa, which in a preferred embodiment (aa) is to
87     code for aspartic acid, but which may also code
88     for alanine.
89 136- FEATURE:
90 137- NAME/KEY: unsure
91 138- LOCATION: (124)...(124)
92 139- OTHER INFORMATION: The num at positions 124 through 124 represents
93     Aaa, which in a preferred embodiment (aa) is to
94     code for alanine, but which may also code for
95     threonine.
96 140- FEATURE:
97 141- NAME/KEY: unsure
98 142- LOCATION: (125)...(125)
99 143- OTHER INFORMATION: The num at positions 125 through 125 represents
100     Aaa, which in a preferred embodiment (aa) is to
101     code for threonine, but which may also code for
102     serine.
103 144- FEATURE:
104 145- NAME/KEY: unsure
105 146- LOCATION: (126)...(126)
106 147- OTHER INFORMATION: The num at positions 126 through 126 represents
107     Aaa, which in a preferred embodiment (aa) is to
108     code for serine, but which may also code for
109     threonine.
110 148- FEATURE:
111 149- NAME/KEY: unsure
112 150- LOCATION: (127)...(127)
113 151- OTHER INFORMATION: The num at positions 127 through 127 represents
114     Aaa, which in a preferred embodiment (aa) is to
115     code for alanine, but which may also code
116     for glutamine.
117

```

## RAW SEQUENCE LISTING

PATENT APPLICATION US/09/500,135

DATE: 08/31/2000

TIME: 12:33:00

Input Set: A:\A688931.app

Output Set: N:\CRF3\08012000\I500135.raw

## 123-130- SEQUENCE: 1

```

121 ggtctatatt atattatttc cataactatac atttaataat tggaa'atit' tttatagg ta
123 ttattctgca aatgaaaaaa aggagaggat aaaga nnn aga ggc aaa aaa gta 113
124 Xaa Arg Gly Lys Lys Val
125
126 taa atc aat tta cta ttt gct tta tga tta atc ttt aag atc aat ttt 141
128 ttp tta Ser Leu Leu Phe Ala Leu Ala Leu tta tta Thr Met Ala Phe
129
130 ggt tta tta tta tta tta tta tta tta tta tta tta tta tta tta tta 159
132 ggt tta tta tta tta tta tta tta tta tta tta tta tta tta tta tta 177
134 ggt tta tta tta tta tta tta tta tta tta tta tta tta tta tta tta 195
136 Lys Tyr Ile Val Gly Phe Lys Gln Thr Met Ser Thr Met Ser Ala Ala
137
138 aag aag aag aag aag aag aag aag aag aag aag aag aag aag aag aag 213
140 Lys Lys Lys Arg Val Ile Ser Glu Lys Gly Gly Lys Val Gln Lys Gln
141
142 tta aag tat ata gac aca aat tta aat aca tta aac aag aag aat ata 231
144 Phe Lys Thr Val Asp Ala Ala Ser Ala Thr Leu Asn Gln Lys Ala Val
145
146 aag aag tta aag aag aag aag aag aag aag aag aag aag aag aag aag 249
148 Lys Glu Leu Lys Lys Asp Pro Ser Val Ala Thr Val Gln Gln Asp His
149
150 gta aat aat aat aat aat aat aat aat aat aat aat aat aat aat aat 267
152 Val Ala His Ala Tyr Ala Gln Ser Val Thr Tyr Gly Val Ser Gln Ile
153
154 aag aag aat aat aat aat aat aat aat aat aat aat aat aat aat aat 285
156 Lys Ala Pro Ala Leu His Asn Ala Thr Tyr Thr Gly Ser Asn Val Lys
157
158 gta aat aat aat aat aat aat aat aat aat aat aat aat aat aat aat 303
160 Val Ala Val Ile Asp Ser Gly Ile Asp Ser Ser His Pro Asp Leu Lys
161
162 gta gca ggc gga gcc agc atg gtt cct tct gaa aca nnn nnn ttc caa 321
164 Val Ala Gly Gly Ala Ser Met Val Pro Ser Glu Thr Xaa Xaa Phe Gln
165
166 gac nnn aac tct cac gga act cac gtt gcc aca gtt gcg gct ctt 339
168 Asp Xaa Asn Ser His Gly Thr His Val Ala Gly Thr Val Ala Ala Leu
169
170 aat aac tca atc ggt gta tta ggc gtt gcg cca agc nnn nnn ctt tac 357
172 Asn Asn Ser Ile Gly Val Leu Gly Val Ala Pro Ser Xaa Xaa Leu Tyr
173
174 gct gta aaa gtt ctc ggt nnn nnn ggt tcc ggc caa tac agc tgg atc 375
176 Ala Val Lys Val Leu Gly Xaa Xaa Gly Ser Gly Gln Tyr Ser Trp Ile
177
178 att aac aat aat aat aat aat aat aat aat aat aat aat aat aat aat 393
180 Ile Asn Gly Ile Gln Trp Ala Ile Ala Ser Ser Thr Asp Val Ile Asn
181
182 aat aat aat aat aat aat aat aat aat aat aat aat aat aat aat aat 411
184 Thr Ser Leu Gly Tyr Pro Ser Gly Ser Ala Ala Leu Lys Ala Ala Val

```

## RAW SEQUENCE LISTING

PARENT APPLICATION US/09/500,135

DATE: 08/01/2009

1992. 12. 20. 9

Input Set: A:\A688931.app

Output Set : N:\CRE3\08012000\1500135.raw

	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	69
--	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	----

see item 10 on Eni Summary  
Ala Leu Ala Leu  
15  
JHt

RAW SEQUENCE LISTING  
 PATENT: ABP110411 N US/09/500,135

DATE: 05/17/2009  
 TIME: 11:11:00

Report Set : A:\A688931.app  
 Report Set : N:\CRF3\08012000\1500135.raw

250 Tyr Val Glu His Asp His Val Ala His Ala Thr Ala Gln Ser Val Pro  
 251 100 105 110  
 252 Thr Gln Val Ser Gln Ile Lys Ala Pro Ala Leu His Ser Gln Gly Thr  
 253 115 120  
 254 Thr Gln Ser Asn Val Lys Val Ala Val Ile Asp Ser Lys Ile Asp Ser  
 255 125 130  
 256 Ser His Thr Asp Leu Lys Val Ala Gly Gly Ala Ser Ile Val Pro Ser  
 257 135 140  
 W--> 258 Glu Thr Xaa Xaa Phe Gln Asp Xaa Asn Ser His Gly Thr His Val Ala  
 259 145 150  
 260 Gly Thr Val Ala His Leu Asn Asn Ser Ile Lys Val Leu Gly Val Ala  
 261 155 160  
 W--> 262 Pro Ser Xaa Xaa Leu Tyr Ala Val Lys Val Leu Gly Xaa Xaa Gly Ser  
 263 165 170  
 264 Gly Ala Tyr Ser Thr Ile Lys Asn Gly Ile Gln His Ala Ile Ala Asn  
 265 175 180  
 266 Asn His Asp Val Ile Asn Met Ser Leu Gly His Pro Ser Gly Ser Ala  
 267 185 190  
 268 Ala Leu His Ala Val Val Asp Lys Ala Val Ala Ser Gly Val Val Val  
 269 195 200  
 W--> 270 Val Ala Ala Ala Gly Asn Glu Gly Xaa Xaa Gly Ser Ser Ser Thr Val  
 271 205 210  
 272 Gly Thr Pro Gly Lys Tyr Pro Ser Val Ile Ala Val Gln Ala Val Asp  
 273 215 220  
 274 Asp Ser Asp Thr Thr Ala Ser Ile Ser Ser Val Gln Thr Gln Leu Asp  
 275 225 230  
 276 Val Met Ala Thr Lys Val Pro Lys Asn Ser Thr Leu Lys Gln Asn Gln  
 277 235 240  
 278 Thr Gln Ala Thr Thr Gln Thr Ser Met Ala Ser Pro His Val Ala Gly  
 279 245 250  
 280 Ala Ala Ala Leu Ile Leu Ser Lys His Pro Asn Tyr Thr Asn Thr Lys  
 281 255 260  
 W--> 282 Val Arg Ser Ser Leu Xaa Asn Thr Thr Thr Lys Leu Gly Asp Ser Phe  
 283 265 270  
 284 Tyr Thr Gly Lys Gln Leu Ile Asn Val Gln Ala Ala Ala Gln  
 285 275 280  
 286 L17 PEI 10 N 13  
 287 L11 MINIPB 13  
 288 L12 TYPEB PEI  
 289 L13 SPANISH KARLINS ANYLIPPEL GARS  
 290 L14 PEI BENDH 13  
 291 Ala Thr Ser Val Pro Tyr Lys Val Ser Gln Ile Lys Ala Pro Ala Leu  
 292 285 290  
 293 His Ser Asp Gln Tyr Thr Gln Ser Asn Val Lys Val Ala Val Ile Asp  
 294 295 300  
 295 Ser Gly Lys Asp Leu Ser His Pro Asp Leu Lys Val Ala Thr Ile Ala  
 296 305 310  
 297 Ser Thr Val Thr Ser Thr Thr Asn Pro Thr Thr Asp Asn Ser His  
 298 315 320

item 10

✓

PSI

**Please Note:**

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

### VERIFICATION SUMMARY

PATENT APPLICATION US/09/500,135

1311-1322/2015

TABLE 1. *Continued*

File Name: A:\A688931.app

N:\CRE3\08012000\1500135.raw

[illegible]